上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
PF-431396 纯度: 98.86%
PF-431396 是具有口服活性的 FAK 和Pyk2 的抑制剂,其 IC50 值分别为 2 nM 和 11 nM。
PF-431396 Chemical Structure
CAS No. : 717906-29-1
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO | ¥990 | In-stock | |
10 mg | ¥900 | In-stock | |
50 mg | ¥2900 | In-stock | |
100 mg | ¥4800 | In-stock | |
200 mg | ¥8000 | In-stock | |
500 mg | 询价 | ||
1 g | 询价 |
* Please select Quantity before adding items.
PF-431396 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- Protein Tyrosine Kinase Compound Library
- Anti-Cancer Compound Library
- Cytoskeleton Compound Library
- Anti-Pancreatic Cancer Compound Library
生物活性 |
PF-431396 is an orally active dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor, with IC50 values of 2 nM and 11 nM, respectively[1][2][3][4]. |
IC50 & Target |
IC50: 2 nM (FAK); 11 nM (PYK2)[1]. |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
PF-431396 has a Kd value of 445 nM for BRD4[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis[3]
|
||||||||||||||||
体内研究 (In Vivo) |
PF-431396 (10 or 30 mg/kg, orally) prevents bone loss induced by estrogen deficiency in rats primarily by stimulating bone formation, providing independent pharmacological confirmation for the function of PYK2 in regulating bone formation[4]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||
分子量 |
506.50 |
||||||||||||||||
Formula |
C22H21F3N6O3S |
||||||||||||||||
CAS 号 |
717906-29-1 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : ≥ 100 mg/mL (197.43 mM) * “≥” means soluble, but saturation unknown. 配制储备液
In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务